Search details
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34462870
2.
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration.
Int J Mol Sci
; 23(7)2022 Mar 29.
Article
in English
| MEDLINE | ID: mdl-35409135
3.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34253871
4.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33024268
5.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33336844
6.
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Pharmacogenomics J
; 21(3): 285-295, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33542444
7.
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Future Oncol
; 17(18): 2315-2324, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33663264
8.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32164906
9.
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.
Oncologist
; 25(10): 886-893, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32353192
10.
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.
Invest New Drugs
; 38(1): 92-98, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31154566
11.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Article
in English
| MEDLINE | ID: mdl-32698790
12.
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer.
BMC Gastroenterol
; 20(1): 133, 2020 May 05.
Article
in English
| MEDLINE | ID: mdl-32370803
13.
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Future Oncol
; 16(4): 21-29, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31914811
14.
Dedifferentiated liposarcoma: when eribulin can make the difference.
Future Oncol
; 16(1s): 21-24, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31872768
15.
Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings.
Radiol Med
; 125(6): 531-537, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32020528
16.
Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Int J Mol Sci
; 21(5)2020 Feb 28.
Article
in English
| MEDLINE | ID: mdl-32121290
17.
Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience.
J Minim Access Surg
; 16(2): 160-165, 2020.
Article
in English
| MEDLINE | ID: mdl-30777992
18.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31003911
19.
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Int J Cancer
; 145(8): 2082-2090, 2019 10 15.
Article
in English
| MEDLINE | ID: mdl-30856283
20.
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
Br J Cancer
; 120(5): 522-526, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30745584